| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash | 309 | 278 | 381 | 886 |
| Accounts receivable, net | 391 | 402 | 405 | 545 |
| Inventory | 3,902 | 4,087 | 4,080 | 4,216 |
| Prepaid expenses and other | 393 | 366 | 231 | 295 |
| Total current assets | 4,995 | 5,133 | 5,097 | 5,942 |
| Property and equipment, gross | NaN | 1,876 | NaN | NaN |
| Less accumulated depreciation | NaN | 1,535 | NaN | NaN |
| Translation adjustment | NaN | -3 | NaN | NaN |
| Property and equipment, net | 329 | 344 | 349 | 363 |
| Right of use assets | 282 | 347 | 410 | 472 |
| Intangibles, net | 68 | 76 | 82 | 88 |
| Goodwill | 1,001 | 1,015 | 1,010 | 1,013 |
| Other assets | 47 | 47 | 47 | 72 |
| Total assets | 6,722 | 6,962 | 6,995 | 7,950 |
| Accounts payable | 1,080 | 1,044 | 1,214 | 1,440 |
| Accrued expenses | 2,647 | 2,447 | 2,874 | 3,003 |
| Current portion of operating lease liability | 246 | 247 | 247 | 239 |
| Convertible notes, at fair value | 1,135 | NaN | NaN | NaN |
| Current portion of long-term debt, net | 72 | 1,262 | 451 | 1,023 |
| Total current liabilities | 5,180 | 5,000 | 4,786 | 5,705 |
| Operating lease liability | 37 | 100 | 162 | 230 |
| Debt, net | 0 | 387 | 504 | 208 |
| Deferred tax liability | 7 | 7 | 4 | 4 |
| Total liabilities | 5,224 | 5,494 | 5,456 | 6,147 |
| Common stock, par value 0.0001 790,000 shares authorized as of march 31, 2026 and december 31, 2025 193,458 and 184,264 shares issue and outstanding as of march 31, 2026 and december 31, 2025, respectively | 19 | 18 | 18 | 18 |
| Additional paid-in capital | 90,029 | 89,330 | 89,207 | 89,083 |
| Accumulated deficit | -88,582 | -87,939 | -87,733 | -87,351 |
| Accumulated other comprehensive income | 32 | 59 | 47 | 53 |
| Total stockholders' equity | 1,498 | 1,468 | 1,539 | 1,803 |
| Total liabilities and stockholders' equity | 6,722 | 6,962 | 6,995 | 7,950 |
CV Sciences, Inc. (CVSI)
CV Sciences, Inc. (CVSI)